Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $320
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $230 to $320.
Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $230 to $320.